Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 477

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

Migraine

Not recruiting

Study on Botulinum Toxin Type A for Preventing Chronic Migraine in Adults

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A - Haemagglutinin Complex

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of SAR444656 for Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years

Cardiomyopathy

Not recruiting

Study on Dapagliflozin to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin

Study of GLPG3667 for Adults with Active Systemic Lupus Erythematosus

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Glpg3667 Fumarate

Psoriatic arthropathy

Not recruiting

Study on Deucravacitinib and Apremilast for Patients with Active Psoriatic Arthritis New to Biologic Treatments or Previously on TNFα Inhibitors

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast

Gout

Not recruiting

Study on the Effects of Tigulixostat and Allopurinol in Patients with Gout and High Uric Acid Levels

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Allopurinol

Study of Pembrolizumab and Axitinib Combination Versus Sunitinib for Patients with Advanced or Metastatic Kidney Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib

Neoplasm

Not recruiting

Study on the Safety and Tolerability of TransCon IL-2 β/γ, Pembrolizumab, and Chemotherapy in Adults with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acp-017

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Treating Moderate to Severe Plaque Psoriasis in Adults

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Jnj-77242113

Dermatitis atopic

Not recruiting

Study on SAR444656 for Adults with Moderate to Severe Atopic Dermatitis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years

Acute myeloid leukaemia+1

Not recruiting

Study of RVU120 for Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride

Dermatitis atopic

Not recruiting

Study on Long-Term Safety and Efficacy of Amlitelimab for Patients with Moderate to Severe Atopic Dermatitis from Previous Trials

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.